These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11678784)

  • 21. Multiple-dose pharmacokinetics and pharmacodynamics of OROS and immediate-release amitriptyline hydrochloride formulations.
    Gupta SK; Shah J; Guinta D; Hwang S
    J Clin Pharmacol; 1998 Jan; 38(1):60-7. PubMed ID: 9597561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
    Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
    Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A benefit-risk assessment of extended-release oxybutynin.
    Michel MC
    Drug Saf; 2002; 25(12):867-76. PubMed ID: 12241127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine.
    Dmochowski R; Chen A; Sathyan G; MacDiarmid S; Gidwani S; Gupta S
    J Clin Pharmacol; 2005 Aug; 45(8):961-8. PubMed ID: 16027408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system.
    Zobrist RH; Quan D; Thomas HM; Stanworth S; Sanders SW
    Pharm Res; 2003 Jan; 20(1):103-9. PubMed ID: 12608543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers.
    Drover DR; Angst MS; Valle M; Ramaswamy B; Naidu S; Stanski DR; Verotta D
    Anesthesiology; 2002 Oct; 97(4):827-36. PubMed ID: 12357147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin.
    Sathyan G; Dmochowski RR; Appell RA; Guo C; Gupta SK
    Clin Pharmacokinet; 2004; 43(14):1059-68. PubMed ID: 15530134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Population Pharmacokinetic Model of (R)- and (S-) Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers.
    Kretschmar M; Suleiman AA; Krause P; Albrecht U; Stein R; Rubenwolf P; Fuhr U; Taubert M
    J Clin Pharmacol; 2021 Jul; 61(7):961-971. PubMed ID: 33368382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo.
    Mizushima H; Takanaka K; Abe K; Fukazawa I; Ishizuka H
    Xenobiotica; 2007 Jan; 37(1):59-73. PubMed ID: 17178634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast.
    Schug BS; Brendel E; Chantraine E; Wolf D; Martin W; Schall R; Blume HH
    Br J Clin Pharmacol; 2002 Jun; 53(6):582-8. PubMed ID: 12047482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy of THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects With Primary Focal Hyperhidrosis.
    Pariser DM; Krishnaraja J; Tremblay TM; Rubison RM; Love TW; McGraw BF
    J Drugs Dermatol; 2017 Feb; 16(2):127-132. PubMed ID: 28300854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS® Formulation of Oxybutynin.
    Olivares-Morales A; Ghosh A; Aarons L; Rostami-Hodjegan A
    AAPS J; 2016 Nov; 18(6):1532-1549. PubMed ID: 27631556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacokinetics of oxybutynin is unaffected by gender and contraceptive steroids.
    Lukkari E; Hakonen T; Neuvonen PJ
    Eur J Clin Pharmacol; 1998 Jan; 53(5):351-4. PubMed ID: 9516036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients.
    Nilsson CG; Lukkari E; Haarala M; Kivelä A; Hakonen T; Kiilholma P
    Neurourol Urodyn; 1997; 16(6):533-42. PubMed ID: 9353802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
    Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
    Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin.
    Birns J; Lukkari E; Malone-Lee JG
    BJU Int; 2000 May; 85(7):793-8. PubMed ID: 10792154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group.
    Anderson RU; Mobley D; Blank B; Saltzstein D; Susset J; Brown JS
    J Urol; 1999 Jun; 161(6):1809-12. PubMed ID: 10332441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.
    Hughes DA; Dubois D
    Pharmacoeconomics; 2004; 22(16):1047-59. PubMed ID: 15524493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pharmacokinetics of oxybutynin in man.
    Douchamps J; Derenne F; Stockis A; Gangji D; Juvent M; Herchuelz A
    Eur J Clin Pharmacol; 1988; 35(5):515-20. PubMed ID: 3234461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Which anticholinergic drug for overactive bladder symptoms in adults.
    Hay-Smith J; Herbison P; Ellis G; Morris A
    Cochrane Database Syst Rev; 2005 Jul; (3):CD005429. PubMed ID: 16034974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.